Literature DB >> 2539966

Suppression of serum 1,25-dihydroxyvitamin D in humoral hypercalcemia of malignancy is caused by elaboration of a factor that inhibits renal 1,25-dihydroxyvitamin D3 production.

S Fukumoto1, T Matsumoto, H Yamoto, H Kawashima, Y Ueyama, N Tamaoki, E Ogata.   

Abstract

Although many patients with humoral hypercalcemia of malignancy exhibit reduced serum 1,25-dihydroxyvitamin D [1,25-(OH)2D] levels, N-terminal fragments of recently identified PTH-related protein as well as PTH itself elevate serum 1,25-(OH)2D concentrations. In the present study, the effect of tumor extracts from human tumor-implanted hypercalcemic nude rat models with high and low serum 1,25-(OH)2D on renal 1,25-(OH)2D3 production was examined using rat kidney cells in culture. Whereas tumors from rats with high serum 1,25-(OH)2D levels (OCC rats) contained only a single peak of cAMP production-stimulating activity (CPSA) in osteogenic sarcoma cells on reverse phase HPLC, tumor extracts from rats with low serum 1,25-(OH)2D levels (UCC rats) contained at least two peaks of CPSA. The main peak (peak A) was estimated to be approximately 17K by gel permeation chromatography, which was the same as the molecular size of the hitherto identified PTH-related protein, and a minor peak of CPSA (peak B) was estimated to be about 25K. When peak A or crude extracts of OCC tumors as well as human PTH-(1-34) were added to primary cultures of rat kidney cells, the production of 1,25-(OH)2D3 was significantly stimulated. In contrast, although peak B or crude UCC tumor extracts had no effect on 1,25-(OH)2D3 production in themselves, when they were added together with peak A or human PTH-(1-34) the stimulation of 1,25-(OH)2D3 production was almost completely inhibited. Both peak A and peak B enhanced cAMP production in cultured kidney cells, and the cAMP production by peak A was not affected by peak B. These results are consistent with the possibility that elaboration of an additional factor from tumor cells may be the mechanism by which serum 1,25-(OH)2D levels are suppressed in patients with humoral hypercalcemia of malignancy. The nature as well as the mechanism of action of this factor remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539966     DOI: 10.1210/endo-124-5-2057

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  Persistent and moderate hypercalcemia related to an ovarian clear cell adenocarcinoma: Pre- and postoperative parathyroid hormone related-peptide and 1,25-dihydroxyvitamin D3 levels.

Authors:  A Benit; J Allard; J Rimailho; J Fauvel; G Escourrou; D Vezzosi; F Donadille; A Bennet; P Caron
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

2.  Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals.

Authors:  Despina Sitara; Mohammed S Razzaque; René St-Arnaud; Wei Huang; Takashi Taguchi; Reinhold G Erben; Beate Lanske
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

3.  Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma.

Authors:  Ganesh S Palapattu; Blaine Kristo; Jacob Rajfer
Journal:  Rev Urol       Date:  2002

Review 4.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

Review 5.  Hypercalcemia in malignancy.

Authors:  G J Strewler; R A Nissenson
Journal:  West J Med       Date:  1990-12

6.  Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone--related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma.

Authors:  Sarika B Shivnani; John M Shelton; James A Richardson; Naim M Maalouf
Journal:  Endocr Pract       Date:  2009-04       Impact factor: 3.443

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.